Compare JILL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JILL | IFRX |
|---|---|---|
| Founded | 1959 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.5M | 266.6M |
| IPO Year | 2017 | 2017 |
| Metric | JILL | IFRX |
|---|---|---|
| Price | $16.21 | $2.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.00 | $6.25 |
| AVG Volume (30 Days) | 71.1K | ★ 1.4M |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $596,549,000.00 | N/A |
| Revenue This Year | $2.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.41 | $0.74 |
| 52 Week High | $18.80 | $2.95 |
| Indicator | JILL | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 50.75 |
| Support Level | $15.92 | $0.95 |
| Resistance Level | $16.89 | $2.94 |
| Average True Range (ATR) | 0.79 | 0.23 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 77.78 | 27.95 |
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.